This press release and report were released
on Feb., 16, 2010. Dr. James A. Simon, director of this web site, is a
past president of the North American Menopause Society
Based on the best available evidence, “Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society” has just been released. Each section of the
previous paper was reviewed by an Advisory Panel of seventeen clinicians and
researchers expert in this area of women’s health using new studies and
findings. The paper was then approved by the NAMS Board of Trustees.
The report from the University of Toronto is welcome news following all the adverse -- even hysterical -- publicity on the risks that hormone therapy may have on breast cancer. This news will be particularly important to the many women who have family histories riddled with breast cancer and who carry the BRCA1 mutation. These women often undergo preemptive surgery for ovarian cancer prophylaxsis (oophorectomy) and/or bilateral mastectomy to avoid becoming yet another breast cancer statistic in their families.
Dr. James A. Simon,
medical director of www.menopausewise.com wanted to be sure
his readers noted this press release and article. The press release is
from the Journal of Women's Health. At the end of the press release is a
link to the article.Here is the release:
John S. Wiener, MD, FAAP, FACS; Haywood Brown, MD, FACOG The decision to circumcise a newborn is best made before delivery, and the task of explaining the risks and benefits involved often falls to the ObGyn. Are you prepared to help your patients make an informed decision?
Dr. James A. Simon, director of this site, felt this was valuable information to pass on about Avandia, a drug for diabetics.
(Feb. 23, 2010)---FDA notified healthcare professional and patients that it is reviewing the primary data from a large, long-term clinical study, RECORD, on possible cardiovascular risks with the diabetes drug, Avandia (rosiglitazone). In addition to the clinical trial, a number of observational studies of the cardiovascular safety of rosiglitazone have been published and FDA has been reviewing these on an ongoing basis.
